

What is claimed is:

Claim 1. (currently amended)

A method of inhibiting inflammation by administration of a antibodies ~~or antigen-binding fragments which binds~~ which bind at least one mammalian chemokine chosen from CXCL9, CXCL10, CXCL11, CCRL1, CCRL2, CCR5, CCL1, CCL2, CCL3, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL19, CCL23-1, CCL23-2, CCL24, CCL26, CCR6, CCL20, CCL25, CCL25-1, CCL25-2, and CCR10 by administration to a mammal in need of anti-inflammatory intervention, of an inflammation-inhibiting effective amount of said antibodies ~~or antigen-binding fragments~~ in a pharmaceutically acceptable carrier.

2. (previously presented)

The method of claim 1 wherein the carrier is a liquid.

3. (previously presented)

The method of claim 1 wherein said mammal is human.

4. (previously presented)

The method of claim 1 wherein the carrier is a solid support.

5. (currently amended)

The method of claim 1 wherein said antibodies ~~or antigen-binding fragments~~ are derived from a human, humanized, chimeric antibody.

6. (currently amended)


The method of claim 1 wherein said antibodies ~~or antigen-binding fragments~~ are administered directly to tissue showing an inflammatory response tissue.

7. (previously presented)
A method of treating a mammal with inflammatory disease by the steps of:
 - 1) exposing tissues from said mammal to differing antibodies which bind to specific chemokines,
 - 2) identifying level of expression of each chemokine based on binding of the each of the differing antibodies, and
 - 3) administering to said mammal those specific antibodies which bind to the over-expressed chemokines.
8. (previously presented)
The method of claim 7 wherein, in step 3, the antibodies are administered directly to the affected tissue.
9. (previously presented)
The method of claim 7 wherein, in step 3, the antibodies are administered parenterally.
10. (previously presented)
The method of claim 7 wherein the antibodies are administered in a liquid carrier.
11. (previously presented)
The method of claim 7 wherein the antibodies are administered on a solid support.
12. (previously presented)
A method of treating a mammal with inflammatory disease by the steps of:
 - 1) identifying the level of particular chemokines using PCR,
 - 2) administering to said mammal those specific antibodies which bind to the over-expressed chemokines in a pharmaceutically acceptable carrier.

13. (previously presented)
The method of claim 12 wherein the antibodies are administered directly to the affected tissue.
14. (previously presented)
The method of claim 12 wherein the antibodies are administered systemically.
15. (currently amended)
The method of ~~the invention~~ claim 12 wherein the antibodies are administered on a solid support.
16. (newly presented)
The method of claim 1 wherein the antibodies are antibodies to CXCL10.
17. (newly presented)
The method of claim 7 wherein the antibodies are antibodies to CXCL10.
18. (newly presented)
The method of claim 12 wherein the antibodies are antibodies to CXCL10.

It is respectfully requested that the claims be examined.

Respectfully submitted

A handwritten signature in cursive script, appearing to read "Glenna Hendricks".

Glenna Hendricks, Reg. No. 32,535